An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer

1

This study identifies plasma biomarkers associated with treatment response to total neoadjuvant therapy in locally advanced rectal cancer patients.
2

A total of 365 differentially expressed genes were found upregulated and 198 downregulated in patients achieving pathological complete response.
3

The multi-marker panel of FASLG, CD160, and LYPD3 showed an area under the curve of 0.791 in predicting pathological complete response.
4

High expression of the multi-marker panel was linked to a higher proportion of EMVI-negative status and increased rates of pathological complete response.
5

The findings suggest that the identified biomarkers warrant further validation in larger, multicenter cohorts for predicting treatment response.

1